$300 million is needed to fund the final phase of FDA testing for Dr. Stanislaw Burzynski's gene-targeted cancer treatments, Antineoplastons.
“Cancer Is Serious Business”
Synopsis
$300 million is needed to fund the final phase of FDA testing for Dr. Stanislaw Burzynski's gene-targeted cancer treatments, Antineoplastons.
Go deeperSynopsis
Dr. Stanislaw Burzynski, a medical doctor and biochemist, faces the Food and Drug Administration (FDA) in a legal battle over his cancer treatment methods. He developed Antineoplastons in the 1970s, which completed Phase II clinical trials in 2009. The documentary details the challenges he encountered while advocating for these therapies. In 2011, Burzynski aimed to secure $300 million to fund the final phase of FDA testing. The film addresses issues of medicine, law, and patient rights in the United States.
Deep Dive
Why Watch
- Meet Dr. Stanislaw Burzynski and his groundbreaking work.
- Find out about the legal battle against the FDA.
- See the potential of Antineoplastons in cancer treatment.
Did You Know
- Dr. Burzynski's Antineoplastons were discovered in the 1970s.
- His therapies completed Phase II FDA-supervised clinical trials in 2009.
- The film indicates that $300 million is needed for final FDA testing in 2011.
- The documentary was directed by Eric Merola.
Perfect For
Frequently Asked Questions
What are Antineoplastons?
Antineoplastons are gene-targeted cancer treatments developed by Dr. Stanislaw Burzynski in the 1970s.
What legal challenges did Dr. Burzynski face?
Dr. Burzynski engaged in a historic legal battle against the Food & Drug Administration (FDA) regarding his cancer treatments.
How much funding was needed for the final phase of FDA testing?
Dr. Burzynski needed to raise $300 million for the necessary funding to enter the final phase of FDA testing in 2011.
What are people saying?
Play More Like This
Where else to watch
Browse more like this
Related Films
Is this your film?
If you made this film or hold the rights to it, we'd like to talk. We can license it and pay you a share of what it earns.
Comments